Glutathione
Evidence: A/C — Established Human EvidenceDermatology / Cosmetic Research
Key facts
- Research areaDermatology / Cosmetic Research
- Research statusunclear
- Study records209 human
- Study-at-a-Glance1published summaries
- Last updated2026-09-07
Evidence Snapshot
What this grade covers
A for endogenous biochemistry (identity, synthesis, GSH/GSSG redox cycle, GST conjugation, redox signaling); B for longer-duration/formulation-specific oral human trials on body GSH pools; C for oral oxidative-stress biomarker and skin/cosmetic pigmentation evidence, which is mixed, small, and heterogeneous; NOT SUPPORTED for IV cosmetic efficacy specifically, which carries separate, substantial route- and product-quality safety concerns (see Negatives/Risks).
Regulatory Context
Not an FDA-approved medicine; commonly sold as a dietary supplement or cosmetic ingredient rather than a regulated drug for a specific indication. In August 2026, FDA issued a compounding safety alert warning against using dietary-supplement-grade glutathione in injectable products, following an adverse-event cluster associated with compounded IV use.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
Glutathione is synthesized inside mammalian cells rather than functioning primarily as a classical extracellular signaling peptide. It is formed from glutamate, cysteine and glycine through a two-step cytosolic pathway. The reduced form is commonly abbreviated GSH; oxidation of two GSH molecules can produce glutathione disulfide, GSSG.
Why are researchers interested in it?
Glutathione is studied because its redox state intersects with oxidative stress, mitochondrial function, xenobiotic metabolism, protein-thiol regulation, and numerous disease-associated cellular states. It is also studied as an exogenous supplement or cosmetic ingredient, although those clinical questions have a much smaller and less consistent evidence base than endogenous glutathione biochemistry.
What does the evidence look like?
Endogenous biochemistry is strong (Grade A) and supported by a large, mature literature. Oral bioavailability and effects on body GSH pools are mixed-to-moderate and formulation/duration-dependent -- one 4-week placebo-controlled trial found no change in oxidative-stress or glutathione measures, while a 6-month trial reported increases in several GSH pools. Skin/cosmetic outcomes are preliminary and limited: several small trials report modest melanin-index changes, but effects are not uniform across sites and systematic reviews describe the evidence as heterogeneous and inconclusive. IV cosmetic efficacy is not established, and chronic IV cosmetic safety evidence is inadequate.
Biggest things to know
Endogenous glutathione biochemistry is extremely well established, but this must not be translated into claims that an exogenous (oral, topical, or IV) glutathione product produces the same effects clinically. Human oral-supplementation results are mixed and formulation-dependent. Skin-pigmentation evidence is preliminary, short-term, and heterogeneous -- not an established 'whitening' effect. Injectable glutathione carries meaningful additional route- and product-quality risk: in August 2026 FDA reported an adverse-event cluster tied to compounded IV glutathione made from dietary-supplement-grade material and warned compounders against that practice.
What don't we know yet?
Not established: that exogenous glutathione reproduces all endogenous GSH functions; that oral glutathione produces consistent clinical health benefits; that any glutathione formulation has a generalized 'detox' effect; that glutathione is an established anti-aging therapy; that cosmetic pigmentation changes are large, durable, or universal; that IV glutathione is an established skin-lightening intervention; or a discrete receptor target suitable for MitoCore's Mechanism Explorer.
Research status
Research Takeaway
Glutathione is L-gamma-glutamyl-L-cysteinyl-glycine, a tripeptide composed of glutamate, cysteine, and glycine, linked through a gamma-glutamyl bond rather than a conventional alpha-carboxyl peptide linkage. The reduced form is commonly abbreviated GSH; oxidation of two GSH molecules produces glutathione disulfide, GSSG.
See all 13 evidence claims →Quick Summary
Glutathione is an endogenous tripeptide made from glutamate, cysteine, and glycine. Its endogenous redox biochemistry -- peroxide handling, enzyme-linked conjugation, and recycling between reduced (GSH) and oxidized (GSSG) forms -- is extremely well established. Human evidence for exogenous (oral, topical, or intravenous) glutathione products is far more limited and route-dependent, and should not be assumed to follow from the endogenous biochemistry.
Mechanism & Research Overview
Cells synthesize glutathione in the cytosol through two enzyme-catalyzed steps: glutamate-cysteine ligase (GCL) performs the first, generally rate-limiting step, followed by glutathione synthetase. Within cells, glutathione participates in redox homeostasis -- glutathione peroxidases couple peroxide reduction to oxidation of GSH, while glutathione reductase uses NADPH to regenerate reduced glutathione from GSSG. Glutathione also serves as a substrate for glutathione S-transferases, which conjugate GSH to many electrophilic compounds; these reactions often support detoxification and elimination, though glutathione conjugation does not make every substrate harmless. Beyond peroxide handling, glutathione participates in redox signaling, including reversible S-glutathionylation of protein cysteine residues, and its pools are distributed across cellular compartments including mitochondria.
Read more about the mechanism
Glutathione should not be described as a receptor agonist. Its core biology is a network of enzyme-linked redox reactions rather than signaling through a discrete ligand-to-receptor target comparable to GLP-1R, GHS-R1a, or the melanocortin receptors. For that reason this page carries no Mechanism Explorer relationship record -- its established mechanisms are represented here in prose instead.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Glutathione is L-gamma-glutamyl-L-cysteinyl-glycine, a tripeptide composed of glutamate, cysteine, and glycine, linked through a gamma-glutamyl bond rather than a conventional alpha-carboxyl peptide linkage. The reduced form is commonly abbreviated GSH; oxidation of two GSH molecules produces glutathione disulfide, GSSG.
Sources: Glutathione synthesis
Supported
Glutathione's endogenous biochemistry -- synthesis, the GSH/GSSG redox cycle, and its role as an enzyme cofactor -- is extremely well established. This does not by itself establish that an exogenous glutathione product (oral, topical, or intravenous) reproduces the same effects clinically; endogenous biology and exogenous-product claims must be evaluated against separate, distinct evidence.
Does not establish
Evidence boundary: Strength of evidence for endogenous glutathione biochemistry must never be used to imply strength of evidence for a commercial/exogenous glutathione product's effects.
Sources: The antioxidant glutathione; Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers; Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Supported
GSH participates in intracellular peroxide detoxification. Glutathione peroxidases use GSH as a reducing substrate during peroxide reduction, generating GSSG; glutathione reductase then regenerates GSH from GSSG using NADPH.
Sources: The antioxidant glutathione
Supported
Glutathione serves as a substrate for glutathione S-transferases, which conjugate GSH to many electrophilic endogenous and xenobiotic compounds. These reactions often support detoxification and elimination, although glutathione conjugation is not universally detoxifying and can, in some cases, participate in bioactivation of the conjugated substrate.
Sources: Glutathione S-transferases--a review; Glutathione conjugation as a bioactivation reaction
Supported
Cells synthesize glutathione in the cytosol through two ATP-dependent enzyme-catalyzed steps: glutamate-cysteine ligase (GCL) catalyzes formation of gamma-glutamylcysteine from glutamate and cysteine (the generally rate-limiting step), and glutathione synthetase adds glycine to form glutathione. Cysteine availability and GCL activity are major determinants of cellular GSH synthesis, and GSH can exert feedback inhibition on the first step.
Sources: Glutathione synthesis; Regulation of glutathione synthesis
Supported
Beyond peroxide handling, glutathione participates in redox signaling, including reversible S-glutathionylation of protein cysteine residues. Although synthesized in the cytosol, intracellular glutathione pools are distributed across compartments including mitochondria, which maintain their own regulated glutathione redox environment.
Sources: Glutathione synthesis and its role in redox signaling; Glutathione and mitochondria
Supported
Oral glutathione does not reliably raise systemic GSH in everyone. Some longer-duration and formulation-specific studies report increases in measured GSH pools, while another placebo-controlled short-term trial found no significant change.
Sources: Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers; Randomized controlled trial of oral glutathione supplementation on body stores of glutathione; Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function; A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical Trial
Supported
Some studies report changes in redox biomarkers with oral glutathione supplementation, but results are not consistent across controlled trials and do not establish clinical benefit.
Sources: Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers; Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Supported
Small trials of some oral and topical glutathione formulations have reported modest changes in measured pigmentation (melanin index), but evidence remains limited, heterogeneous, short-term, and not uniformly positive across all measured sites or endpoints.
Sources: Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study; Glutathione and its antiaging and antimelanogenic effects; Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women; Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial; The clinical effect of glutathione on skin color and other related skin conditions: A systematic review; Glutathione as a skin-lightening agent and in melasma: a systematic review
Supported
Some small cosmetic studies have reported changes in wrinkle, elasticity, or hydration measures associated with glutathione use; these findings require stronger replication before supporting a broad anti-aging claim.
Sources: Glutathione and its antiaging and antimelanogenic effects
Supported
Evidence for intravenous glutathione as a cosmetic skin-lightening treatment is inadequate, while route- and compounding-related safety concerns are substantial. A small IV pilot in a non-cosmetic condition found no significant efficacy signal, and systematic review has judged IV glutathione unfavorable for cosmetic use given weak efficacy support and greater safety concerns.
Sources: Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease; Intravenous glutathione for skin lightening: Inadequate safety data; Glutathione as a skin-lightening agent and in melasma: a systematic review
Supported
Glutathione is not safe as an unqualified, universal statement. Short oral and topical trials generally report few serious adverse events, but long-term and route-specific safety evidence is incomplete, and injectable use introduces additional risks not captured by oral/topical studies.
Sources: Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study; Glutathione and its antiaging and antimelanogenic effects; FDA reminds compounders not to use dietary supplement grade glutathione for injectables
Supported
Injectable glutathione introduces route- and product-quality risks not captured by short oral/topical studies. In August 2026, FDA reported an adverse-event cluster (fever, chills, pain, dizziness, shock/sepsis-like symptoms, some hospitalizations) involving compounded IV glutathione made from dietary-supplement-grade material, and warned compounders against using such material for injectable drugs. This is a product-quality and route-specific signal, not evidence that glutathione itself intrinsically causes these events.
Does not establish
Evidence boundary: The FDA event cluster was associated with compounded product quality and endotoxin exposure, not proof that pure glutathione intrinsically causes the reported adverse events.
Sources: FDA reminds compounders not to use dietary supplement grade glutathione for injectables
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
In August 2026, FDA reported an adverse-event cluster (fever, chills, pain, dizziness, shock/sepsis-like symptoms, some hospitalizations) linked to compounded IV glutathione made from dietary-supplement-grade material, and warned compounders against using such material for injectable drugs. This reflects sterility, ingredient-quality, and endotoxin risk associated with the injectable route and product sourcing -- not proof that glutathione itself intrinsically causes these events.Higher-Priority Safety Consideration
A systematic review found no adequate studies establishing chronic IV glutathione safety for cosmetic skin lightening, and a separate systematic review judged IV glutathione unfavorable given weak efficacy support and greater safety concerns relative to oral/topical routes.Safety Consideration
Short oral/topical trials generally report few serious adverse events, but this should not be generalized to all formulations or durations -- long-term human safety evidence is limited.Safety Consideration
Cosmetic trials are short-term and formulation-specific; systematic reviews emphasize heterogeneity and inconsistent findings, and durability of any measured pigmentation change after stopping use has not been established.
Research Areas Being Studied
Research areas discussed on this page reflect the Dermatology / Cosmetic Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
Show findings from 9 human studies
- A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical Trial (2026):
- Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial (2021):
- Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function (2018):
- Glutathione and its antiaging and antimelanogenic effects (2017):
- Randomized controlled trial of oral glutathione supplementation on body stores of glutathione (2015):
- Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women (2014):
- Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study (2012):
- Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers (2011):
- Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease (2009):
Study Tables by Evidence Type
20 study records · 1 with a Study-at-a-Glance summary
Human Studies & Clinical Data(9)
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
2015NCT01044277 · PMID 24791752 · DOI 10.1007/s00394-014-0706-z
Study-at-a-Glance available
- Population / Model
- 54 nonsmoking healthy adults
- Dose / Duration / Finding
Randomized, double-blind, placebo-controlled trial. Reported increases in several GSH pools (blood, erythrocytes, plasma, lymphocytes, buccal cells) over time, most prominently in the higher-intake group; levels returned toward baseline after washout.
- Duration:
- 6 months
Key takeaway
In a 6-month trial in 54 healthy adults, daily oral glutathione raised glutathione levels in blood and other body compartments, and levels returned to baseline after stopping. This tested biomarkers in healthy people, not any disease.
Study at a Glance
Study at a Glance
Plain-language summary of: Randomized controlled trial of oral glutathione supplementation on body stores of glutathione
Does taking glutathione by mouth raise glutathione levels in the body of healthy adults?
Evidence status
What was being studied?
Whether taking glutathione by mouth for 6 months raises glutathione levels in the body. Glutathione is the body's main internal antioxidant. The study measured glutathione in blood, red blood cells, plasma, white blood cells (lymphocytes) and cells scraped from the inside of the cheek, plus markers of oxidative stress. A group of immune markers was measured in a subset of participants. It did not test whether glutathione prevents or treats any disease.
Who participated?
Healthy adults aged 30 to 79 who did not smoke and were not taking glutathione or high-dose antioxidant supplements. The journal abstract reports 54 non-smoking adults; the registry lists 61. People with cancer, diabetes or heart disease were excluded.
How was the study done?
A 6-month, randomized, double-blind, placebo-controlled trial. Participants took glutathione at a low dose (250 mg a day), a high dose (1,000 mg a day) or placebo. Glutathione was measured at baseline and after 1, 3 and 6 months, and again after a 1-month washout period without the supplement. This summary uses the PubMed abstract of the European Journal of Nutrition report and the registry record; the registry posts no results and the full paper was not reviewed.
Key results
Glutathione levels in blood rose after 1, 3 and 6 months at both doses compared with baseline. At 6 months in the high-dose group, glutathione was up 30% to 35% in red blood cells, plasma and lymphocytes and 260% in cheek cells (P<0.05); in the low-dose group it was up 17% in blood and 29% in red blood cells (P<0.05). Increases were mostly dose- and time-dependent and returned to baseline after a 1-month washout. The ratio of oxidized to reduced glutathione in whole blood fell in both dose groups after 6 months, a sign of lower oxidative stress. Natural killer cell activity more than doubled in the high-dose group versus placebo at 3 months (P<0.05).
| Measure | Group | Timepoint | Reported value |
|---|---|---|---|
| Rise in glutathione in red blood cells, plasma and lymphocytes | High dose (1,000 mg/day) | 6 months | +30% to +35%P<0.05 versus baseline. |
| Rise in glutathione in cells from the inside of the cheek | High dose (1,000 mg/day) | 6 months | +260%P<0.05. |
| Rise in glutathione in whole blood and red blood cells | Low dose (250 mg/day) | 6 months | +17% (blood) and +29% (red blood cells)P<0.05. |
| Natural killer cell cytotoxicity (immune marker, subset of participants) | High dose vs placebo | 3 months | More than doubledP<0.05; a secondary outcome measured only in a subset. |
What does this mean?
Safety findings
Safety information was not available in the source reviewed. The PubMed abstract does not report adverse events, side effects or participant drop-outs, and the registry posts no results.
Important limitations
- The study measured biomarkers in healthy volunteers; it did not test any disease, symptom or health outcome.
- Only the PubMed abstract was reviewed, not the full paper, so group sizes, individual results and safety details are not covered.
- The abstract reports 54 participants while the registry lists 61, and the sources do not explain the difference.
- The immune markers were secondary outcomes measured in only a subset of participants.
- Participants were healthy, non-smoking adults aged 30 to 79; results may not apply to people with disease, to smokers or to other doses.
- The registry posts no results, so the figures could not be cross-checked.
Regulatory context
- Investigational use studied here
- This study tested oral glutathione at 250 or 1,000 mg a day as a supplement in healthy adults. It was not tested as a treatment for any disease, and it is not an FDA-approved medicine for any condition.
A search of Drugs@FDA by active ingredient on 2026-10-09 found glutathione disulfide only as an ingredient of a prescription sterile solution (BSS Plus) and no oral glutathione product. This research summary does not imply that glutathione is approved, or that any product containing it is safe or effective.
Where sources differ
- Number of participants: ClinicalTrials.gov reports 61 participants (actual enrollment); European Journal of Nutrition abstract reports 54 non-smoking adults. The registry counts 7 more participants than the published abstract. The reason for the difference is not established from the sources reviewed.
Sources
- Trial record
- ClinicalTrials.gov NCT01044277 (Glutathione Supplementation and Health study; no results posted) — ClinicalTrials.gov
- Primary results source
- European Journal of Nutrition 2015, oral glutathione supplementation trial (PubMed abstract) (the peer-reviewed publication that reports the results of this trial) — PubMedClinicalTrials.gov is the trial record but posts no results for this study, so the results come from this publication.
- Sources reviewed
- Trial registry record only · Abstract only — full text not reviewed · Regulatory document.
Other sources for this study (1)
- Drugs@FDA (openFDA, by active ingredient) and DailyMed lookups for glutathione, accessed 2026-10-09 — Regulator (FDA / EMA) · Glutathione disulfide appears in Drugs@FDA only as an ingredient of a prescription sterile solution (BSS Plus); no oral glutathione product was found.Content reviewed for this summary
This summary is a plain-language reading aid written by MitoCore. It does not replace the original study, which remains the authoritative source. Research information only, not medical advice.
A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans: A Randomized Crossover Clinical Trial
2026PMID 41897500 · DOI 10.3390/antiox15030354
- Population / Model
- 14 healthy adults (pharmacokinetic phase)
- Dose / Duration / Finding
Randomized, double-blind crossover pilot comparing micellar, standard, and liposomal oral formulations. Supports formulation-dependent changes in whole-blood GSH and related metabolites. Very small pilot; industry R&D affiliation reported in the PubMed record; does not prove health or cosmetic outcomes.
Show full finding
Combination of topical and oral glutathione as a skin-whitening agent: a double-blind randomized controlled clinical trial
2021PMID 33871071 · DOI 10.1111/ijd.15573
- Population / Model
- 46 participants
- Dose / Duration / Finding
Randomized controlled trial of oral placebo vs. oral glutathione, with topical placebo/glutathione applied to opposite facial sides. Some colorimetric outcomes favored combined oral + topical exposure. Small, short-term, complex design; does not establish a durable generalized effect.
Show full finding- Duration:
- 8 weeks
Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function
2018PMID 28853742 · DOI 10.1038/ejcn.2017.132
- Population / Model
- 12 healthy adults
- Dose / Duration / Finding
Uncontrolled pilot study. Reported increases in whole-blood, erythrocyte, plasma, and PBMC GSH pools and changes in several oxidative-stress/immune markers. Very small sample; cannot establish clinical benefit.
- Duration:
- 1 month
Glutathione and its antiaging and antimelanogenic effects
2017PMID 28490897 · DOI 10.2147/CCID.S128339
- Population / Model
- Healthy women
- Dose / Duration / Finding
Randomized, double-blind, placebo-controlled, three-arm trial (oral reduced GSH, oral GSSG, placebo). Several melanin/UV/wrinkle measures favored glutathione groups at selected sites; not every endpoint/site showed a uniform effect. No serious adverse effects reported.
Show full finding- Duration:
- 12 weeks
Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women
2014PMID 25378941 · DOI 10.2147/CCID.S68424
- Population / Model
- 30 healthy women aged 30-50
- Dose / Duration / Finding
Randomized, double-blind, matched-pair, placebo-controlled split-face trial of topical 2% GSSG. Lower melanin index and changes in some skin-condition measures on treated sites. Two authors were affiliated with Kyowa Hakko Bio Co., Ltd., a commercial ingredient company.
Show full finding- Duration:
- 10 weeks
Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study
2012PMID 20524875 · DOI 10.3109/09546631003801619
- Population / Model
- 60 healthy medical students
- Dose / Duration / Finding
Randomized, double-blind, placebo-controlled trial measuring melanin index at six body sites. Melanin indices declined across measured sites, but statistically significant differences versus placebo were observed at only two of the six sites. Study itself noted long-term safety was not established.
Show full finding- Duration:
- 4 weeks
Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers
2011PMID 21875351 · DOI 10.1089/acm.2010.0716
- Population / Model
- 40 healthy adults (39 completed the trial)
- Dose / Duration / Finding
Randomized, double-blind, placebo-controlled trial. No significant between-group change in urinary F2-isoprostanes, urinary 8-OHdG, or erythrocyte reduced/oxidized glutathione indices.
- Duration:
- 4 weeks
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
2009PMID 19230029 · DOI 10.1002/mds.22401
- Population / Model
- 21 participants with Parkinson disease
- Dose / Duration / Finding
Randomized, placebo-controlled, double-blind IV pilot. No significant difference in UPDRS outcomes; short-term tolerability was similar between groups. Very small and short; disease-specific; does not establish cosmetic efficacy or chronic IV safety.
- Duration:
- 4 weeks
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries(1)
FDA reminds compounders not to use dietary supplement grade glutathione for injectables
2026- Population / Model
- Dose / Duration / Finding
FDA reported at least 30 patients with adverse events after IV glutathione (alone or in combinations) from compounded products using dietary-supplement-grade glutathione, including fever, chills, pain, dizziness, and shock/sepsis-like symptoms, with some hospitalizations. FDA associated the cluster with inappropriate injectable ingredient quality and endotoxin risk, and warned compounders against using dietary-supplement-grade material for injectable drugs. This is a product-quality/route signal, not proof that pure glutathione intrinsically causes these events.
Show full finding
Review Articles / Secondary Sources(10)
Glutathione as a skin-lightening agent and in melasma: a systematic review
2025PMID 39444151 · DOI 10.1111/ijd.17535
- Population / Model
- Dose / Duration / Finding
Systematic review. Found multiple oral/topical studies reporting melanin-index changes but substantial heterogeneity and mixed risk of bias; judged IV glutathione unfavorable because efficacy support is weak and safety concerns are greater.
The antioxidant glutathione
2023PMID 36707132
- Population / Model
- Dose / Duration / Finding
Review of GSH/GSSG redox couple biology: glutathione peroxidases reduce peroxides using GSH as substrate; glutathione reductase regenerates GSH from GSSG using NADPH.
The clinical effect of glutathione on skin color and other related skin conditions: A systematic review
2019PMID 30895708 · DOI 10.1111/jocd.12910
- Population / Model
- Dose / Duration / Finding
Systematic review. Evidence was considered inconclusive because of study quality and inconsistent findings, although a trend toward lighter skin at some sun-exposed sites was observed.
Intravenous glutathione for skin lightening: Inadequate safety data
2016PMID 27499402 · DOI 10.7196/SAMJ.2016.v106i8.10878
- Population / Model
- Dose / Duration / Finding
At the time of review, there were no adequate studies establishing chronic IV glutathione safety for cosmetic skin lightening.
Glutathione and mitochondria
2014PMID 25024695
- Population / Model
- Dose / Duration / Finding
GSH is synthesized in the cytosol and distributed to other compartments including mitochondria, which maintain their own regulated glutathione redox environment.
Glutathione synthesis
2013PMID 22995213 · DOI 10.1016/j.bbagen.2012.09.008
- Population / Model
- Dose / Duration / Finding
Review of glutathione biosynthesis: glutamate-cysteine ligase (GCL) catalyzes the rate-limiting first step, glutathione synthetase the second; cysteine availability and GCL activity are major determinants of cellular GSH synthesis.
Glutathione synthesis and its role in redox signaling
2012PMID 22504020
- Population / Model
- Dose / Duration / Finding
Review covering glutathione synthesis and redox signaling, including reversible protein S-glutathionylation of cysteine residues.
Regulation of glutathione synthesis
2009PMID 18601945 · DOI 10.1016/j.mam.2008.05.005
- Population / Model
- Dose / Duration / Finding
Review of GSH synthesis regulation: GCL rate limitation, cysteine availability, and feedback inhibition of the first synthesis step by GSH itself.
Glutathione conjugation as a bioactivation reaction
2001PMID 11154735 · DOI 10.1016/S0009-2797(00)00214-3
- Population / Model
- Dose / Duration / Finding
Glutathione conjugation is not universally detoxifying -- in some cases GST-catalyzed conjugation participates in bioactivation of the conjugated substrate rather than its elimination.
Glutathione S-transferases--a review
1999PMID 10101214
- Population / Model
- Dose / Duration / Finding
Review of GST-catalyzed conjugation of GSH to electrophilic substrates, generally supporting downstream metabolism/excretion.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
This page distinguishes glutathione's well-established endogenous biochemistry from the much more limited, route-dependent human evidence for exogenous (oral, topical, or intravenous) glutathione products. Nothing here is medical advice, a recommendation, a dosing instruction, or a claim that any product treats, prevents, or cures a disease.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-09-07.
Follow research updates for Glutathione
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.